Inactive Instrument

Other languages Clarus Therapeutics Holdings, Inc.

Equities

CRXT

US18271L1070

Other languages

Unlock all the news: Be the first to know and act before the market!

Clarus Therapeutics Holdings, Inc. Went Out of Business	23-02-28
First Motion for Exclusivity Period Extension Approved For Clarus Therapeutics Holdings, Inc.	23-01-16
First Motion for Exclusivity Period Extension Filed by Clarus Therapeutics Holdings, Inc.	22-12-28
First Amended Combined Liquidation Plan and Disclosure Statement Approved on Interim Basis for Clarus Therapeutics Holdings, Inc.	22-12-22
Clarus Therapeutics Holdings, Inc. Announces Termination of Robert Dudley as Chief Executive Officer	22-10-31
Clarus Therapeutics Holdings, Inc. Announces Executive Changes	22-10-31
Motion for Joint Administration Approved for Clarus Therapeutics Holdings, Inc.	22-09-07
Motion for Joint Administration Filed by Clarus Therapeutics Holdings, Inc.	22-09-05
Clarus Therapeutics Holdings, Inc. Filed for Bankruptcy	22-09-05
Sector Update: Health Care Stocks a Rare Positive in Friday Trading	22-08-19
Clarus Therapeutics Holdings Inc Contemplates Bankruptcy	22-08-19
Clarus Therapeutics Posts Higher Revenue in Q2; Planned 40% Workforce Cut to be Completed in August	22-08-18
Clarus Therapeutics Holdings, Inc. Announces Appointment of Steven Bourne as Principal Accounting Officer, Effective August 31, 2022	22-08-18
Clarus Therapeutics Posts Higher Revenue in Q2	22-08-18
Clarus Therapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-18
Clarus Therapeutics Holdings, Inc. Announces Reduction in Workforce by Approximately 40% of Total Headcount	22-08-18
Clarus Therapeutics Holdings, Inc. Announces Resignation of Joseph Hernandez from Board of Directors and Committees	22-08-09
Oragenics Appoints Kimberly Murphy as President, CEO	22-06-23
Clarus Therapeutics Gets US Patent for Testosterone Replacement Product	22-05-18
Clarus Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Clarus Therapeutics Holdings, Inc.

Equities

CRXT

US18271L1070

Other languages

Filters